Tainan, Taiwan, March 07, 2025 — Advanced Biomed Inc. (NASDAQ: ADVB), a Taiwan-based biotechnology firm specializing in early cancer screening, diagnosis, and treatment, announced the completion of its initial public offering (IPO) today. The company offered 1,640,000 shares of common stock at $4.00 each, generating gross proceeds of $6.56 million before accounting for underwriting discounts and other offering-related expenses. Trading of the shares commenced on the Nasdaq Capital Market on March 6, 2025, under the ticker symbol “ADVB.”
The offering was a firm commitment underwriting. Furthermore, the underwriter has the option to purchase up to 246,000 additional shares of common stock at the IPO price, less discounts and commissions, within 45 days of the closing date to cover any over-allotments.
The company intends to allocate the IPO proceeds to: (i) in-vitro diagnostics (IVD) clinical research, chip design and development, facility upgrades, and expansion into new markets; (ii) marketing and sales initiatives; and (iii) general working capital needs.
Craft Capital Management LLC served as the underwriter for the offering. VCL Law LLP provided U.S. securities counsel to the Company, while Ortoli Rosenstadt LLP acted as U.S. securities counsel to the Underwriter.
The offering was made through a registration statement on Form S-1 (File No. 333-272110) filed with the Securities and Exchange Commission (SEC), which was declared effective on February 11, 2025. The offering was conducted solely through a prospectus, which can be accessed for free on the SEC’s EDGAR website at . A copy of the prospectus can also be obtained from Craft Capital Management LLC via email at , by mail at 377 Oak St, Lower Concourse, Garden City, NY 11530, or by phone at +1 (800) 550-8411.
This press release does not constitute an offer to sell or a solicitation of an offer to buy the described securities. Furthermore, these securities will not be offered or sold in the United States without registration or an applicable exemption from registration, nor will there be any offer, solicitation, or sale of these securities in any state or jurisdiction where such activity would be unlawful before registration or qualification under local securities laws.
About Advanced Biomed Inc.
Since its establishment in 2014, Advanced Biomed Inc. has been dedicated to integrating various interdisciplinary technologies to create its microfluidic technology platform. The company’s goal is to offer fast and cost-effective assay products and services for cancer patients. Advanced Biomed’s innovative devices include A+Pre, AC-1000, A+CellScan, and A+SCDrop, along with the corresponding biochips: A+Pre Chip, AC-1000 CTC Enrichment Chip, and A+CellScan Chip. The company’s technologies and products are designed for early cancer screening and detection, diagnosis and staging, and treatment monitoring through the detection of circulating tumor cells and related markers in blood samples, single circulating tumor cell capture, and single-cell sorting and analysis. In addition, the company has finalized R&D for four matching immunostaining kits, A+CTCE, A+CTCM, A+EMT, and A+CM, using multiplexed staining with fluorescent antibodies to identify tumor cell types. The company also offers A+LCGuard, a product for the early screening of lung cancer to aid in determining whether pulmonary nodules are benign or malignant. With primary operations, design, and development located in Taiwan, Advanced Biomed is expanding in China and planning to establish operation centers in North America and Europe.
Forward-Looking Statement
This press release contains forward-looking statements that involve plans, objectives, goals, strategies, future events, performance, underlying assumptions, and other statements that are not statements of historical facts. Terms such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” “continue” and similar expressions identify forward-looking statements. These statements are not guarantees of future performance and involve risks and uncertainties that could cause actual results to differ materially from expectations. These uncertainties and risks include, but are not limited to, market conditions and other factors discussed in the “Risk Factors” section of the Registration Statement filed with the SEC. Investors are cautioned not to place undue reliance on these forward-looking statements. Additional factors are discussed in the Company’s filings with the SEC, which are available at . The Company undertakes no obligation to revise these forward-looking statements to reflect events or circumstances that occur after the date of this release.
For more information, please contact:
Advanced Biomed Inc.
Mingze Yin
Email:
Mobile: +852-95050429
“`